将全基因组关联研究精神疾病药理治疗相关联
该生物信息学研究评估了4种精神疾病的全基因组关联研究(GWAS)遗传变异与当前药物治疗靶点之间的对应关系,使用4种生物信息学数据模态进行映射。结果显示,除双相障碍在蛋白-蛋白相互作用网络映射下显示出关联外,治疗靶点与GWAS涉及基因的总体对应程度很少超过随机预期。
要点
- 在2232个药物靶点基因中,仅双相障碍在蛋白-蛋白相互作用网络映射下显示与GWAS遗传变异存在关联。
- 大多数疾病对和映射方法未显示治疗靶点与GWAS涉及基因之间的显著对应。
- 作者认为,驱动精神疾病风险的遗传架构可能与当前靶向症状表现的药理机制不同。
核心结论
- 跨模态的较低对应程度提示,驱动精神疾病风险的遗传架构可能与当前用于靶向症状表现的药理治疗机制不同。
- 作者认为,基于 refined phenotypes(包括治疗反应)的GWAS新方法可能有助于长期将疾病风险基因映射到药理治疗。
研究设计与样本
- 生物信息学研究,纳入注意缺陷/多动障碍、双相障碍、精神分裂症和重性抑郁障碍4种精神疾病。
- 使用DrugBank数据库中列出的2232个获批治疗靶点基因作为候选集,每个基因针对每种疾病独立赋予2个分数:一个基于其作为治疗靶点的参与,另一个基于GWAS涉及的单核苷酸变异(SNV)与基因之间的映射,映射依据4种生物信息学数据模态之一:SNV位置、蛋白-蛋白相互作用(PPI)网络上的基因距离、脑表达数量性状位点(eQTL)和脑内基因表达模式。
- 研究数据分析时间为2023年11月至2024年9月。
主要发现
- 纳入功能生物信息学数据(以PPI网络形式)揭示了双相障碍的关联(置换P值[P-perm] = 7 × 10⁻⁴;加权相似性分数,经验值[ρ-emp] = 0.1347;随机加权相似性分数均值[标准差] [ρ-rand] = 0.0704 [0.0163])。
- 然而,精神疾病中治疗靶点与GWAS涉及基因的总体对应程度很少超过随机预期。
- 探索性分析评估跨疾病的GWAS识别遗传架构与治疗靶点之间的重叠,发现大多数疾病对和映射方法未显示显著对应。
关键数值与推荐
- 使用加权相似性度量,采用严格的零假设检验框架,通过将特定疾病识别的关联与随机选择的治疗集进行比较来量化匹配的特异性。
- 双相障碍在PPI网络映射下:P-perm = 7 × 10⁻⁴;ρ-emp = 0.1347;ρ-rand均值(标准差)= 0.0704(0.0163)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Large-scale genome-wide association studies (GWAS) should ideally inform the development of pharmacological treatments, but whether GWAS-identified mechanisms of disease liability correspond to the pathophysiological processes targeted by current pharmacological treatments is unclear. OBJECTIVE: To investigate whether functional information from a range of open bioinformatics datasets can elucidate the relationship between GWAS-identified genetic variation and the genes targeted by current treatments for psychiatric disorders. DESIGN, SETTING, AND PARTICIPANTS: Associations between GWAS-identified genetic variation and pharmacological treatment targets were investigated across 4 psychiatric disorders-attention-deficit/hyperactivity disorder, bipolar disorder, schizophrenia, and major depressive disorder. Using a candidate set of 2232 genes listed as targets for all approved treatments in the DrugBank database, each gene was independently assigned 2 scores for each disorder-one based on its involvement as a treatment target and the other based on the mapping between GWAS-implicated single-nucleotide variants (SNVs) and genes according to 1 of 4 bioinformatic data modalities: SNV position, gene distance on the protein-protein interaction (PPI) network, brain expression quantitative trail locus (eQTL), and gene expression patterns across the brain. Study data were analyzed from November 2023 to September 2024. MAIN OUTCOMES AND MEASURES: Gene scores for pharmacological treatments and GWAS-implicated genes were compared using a measure of weighted similarity applying a stringent null hypothesis-testing framework that quantified the specificity of the match by comparing identified associations for a particular disorder with a randomly selected set of treatments. RESULTS: Incorporating information derived from functional bioinformatics data in the form of a PPI network revealed links for bipolar disorder (P permutation [P-perm] = 7 × 10-4; weighted similarity score, empirical [ρ-emp] = 0.1347; mean [SD] weighted similarity score, random [ρ-rand] = 0.0704 [0.0163]); however, the overall correspondence between treatment targets and GWAS-implicated genes in psychiatric disorders rarely exceeded null expectations. Exploratory analysis assessing the overlap between the GWAS-identified genetic architecture and treatment targets across disorders identified that most disorder pairs and mapping methods did not show a significant correspondence. CONCLUSIONS AND RELEVANCE: In this bioinformatic study, the relatively low degree of correspondence across modalities suggests that the genetic architecture driving the risk for psychiatric disorders may be distinct from the pathophysiological mechanisms currently used for targeting symptom manifestations through pharmacological treatments. Novel approaches incorporating insights derived from GWAS based on refined phenotypes including treatment response may assist in mapping disorder risk genes to pharmacological treatments in the long term.
引用
- Arnatkeviciute A, Fornito A, Tong J, et al. Linking Genome-Wide Association Studies to Pharmacological Treatments for Psychiatric Disorders. JAMA Psychiatry. 2025. PMID: 39661350. doi:10.1001/jamapsychiatry.2024.3846
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。